After 11 years in pharma commercial strategy, I have sat through more "post-conference debriefs" than I care to count. In those rooms, the discussion usually devolves into a game of vanity metrics: How many leads did we scan? How cool was our booth? Did the CEO get a photo with a KOL?
Most of the time, the answer is: "None of this is moving the needle on formulary access."
The question I get asked most by leadership—usually when budgets are getting slashed—is whether smaller, targeted events like The Health Management Academy (THMA) forums can actually replace the massive, bloated circus of a major congress like ASCO or the networking frenzy of BIO. The short answer? They aren't substitutes. They are tools for entirely different stages of the commercial lifecycle. If you treat them as interchangeable, you’re just lighting capital on fire.
The Trap: Choosing Events by Brand, Not Outcome
The biggest mistake commercial teams make is confusing "visibility" with "adoption." A giant congress is a megaphone; a forum is a scalpel. If you show up to a massive medical congress expecting to drive a specific P&T committee decision, you’ve miscalculated your strategy. If you show up to an executive forum expecting to launch a product to a general audience, you’re in the wrong place.
Before you commit to a sponsorship or send your team to a conference, you need to define your primary outcome. Ask yourself: Is this for corporate development, commercial intelligence, or system-level adoption?
The Big Congresses: The Anchors of Partnering and Licensing
When we look at events like BIO, the goal isn't "awareness" in the traditional sense; it’s business development. The BIO Partnering platform is arguably the most efficient engine in our industry for early-to-mid-stage pipeline movement.
At these massive congresses, the value is scale. You aren't there to influence the formulary of a single regional hospital system. You are there to:
- Identify potential licensing partners or M&A targets. Validate competitive positioning against global benchmarks. Compress six months of email tag into three days of back-to-back meetings.
The Verdict: If your objective is asset valuation, partnering, or high-level strategic alignment, the big congress is your home. If your objective is getting your drug on a specific health system's list of preferred agents, the big congress is a black hole where your strategy will go to die.
THMA Forums: The Reality of Formulary and Health System Adoption
This is where we shift from "market buzz" to "market reality." THMA forums are fundamentally different. They aren't trade shows; they are executive peer-to-peer dialogues. When you step into a real-world evidence conference 2026 room at an Academy forum, you aren't fighting for attention on a crowded expo floor.
The goal here is adoption. These forums bring together the C-suite and decision-makers from major health systems. This is where you test your value proposition against the actual pain points of hospital administrators and health system leaders.
Here is what you actually gain from these forums:
Formulary Reality Check: You learn exactly why a drug that looks great in a journal fails in a real-world hospital environment due to operational or pharmacy-spend constraints. Competitive Intelligence: You hear directly from the people who hold the purse strings about how they view your competitors. It’s significantly more accurate than third-party market research reports. System-Level Access: You build relationships with the gatekeepers who influence the pathways that determine patient access.Comparison Matrix: Executive Forums vs. Big Congresses
To help you decide where to allocate your next quarter’s travel and sponsorship budget, look at this breakdown. It’s based on where these events actually deliver ROI, not where the marketing deck says they do.
How to Choose Your Strategy: A Simple Checklist
Stop overcomplicating your conference strategy. If you can’t answer these three questions, don’t book EMA and MHRA updates for 2027 the flight. And for the love of all that is holy, don't call every meeting "must-attend." Most aren't.
The 3-Question Conference Selection Checklist:
- What is the specific commercial outcome? (If the answer is "we need to be there because everyone else is," cancel the trip.) Who is the decision-maker in the room? (Does the forum have the people who can change the formulary, or just the people who read the brochures?) Is the format conducive to the outcome? (If you need to discuss confidential formulary hurdles, a 10x10 booth with loud music is the wrong environment.)
The "Fierce" Reality: Integrating Commercial Intelligence
While THMA gives you the health system perspective, events like Fierce Pharma Week provide that vital layer of competitive intelligence and commercial execution strategy. They sit in the middle—serving as a bridge between the clinical-heavy congresses and the policy-heavy forums. They are excellent for pressure-testing your commercial go-to-market plan against industry standards.
If you are planning your annual portfolio, view these three tiers as a funnel:
The Broad Top: Big Congresses (BIO, ASCO) for partnership building and market sensing. The Middle: Tactical forums (Fierce Pharma) for commercial execution and competitive benchmarking. The Narrow Bottom: Targeted forums (THMA) for specific health system adoption and formulary access.Conclusion: Stop Collecting Lanyards
I’ve seen too many commercial teams burn their entire budget on one "big win" at a major congress, only to find themselves completely locked out of the health systems that actually drive prescribing volume.
Stop trying to make one event do everything. A big congress is a PR play and a networking engine. An executive forum is a strategic deep dive into the guts of the US healthcare system. Don't look for a "substitute"—look for the right tool for the specific job you have at hand. If you want to move the needle on adoption, trade your lanyard collection for a seat at the table where the decisions are actually made.